{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:40:18Z","timestamp":1790451618018,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.seizure.2021.05.014","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T04:29:29Z","timestamp":1621830569000},"page":"5-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Two-center experience of cannabidiol use in adults with Dravet syndrome"],"prefix":"10.1016","volume":"91","author":[{"given":"Katri","family":"Silvennoinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Mantoan","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Nashef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Hudgell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Balestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay M","family":"Sisodiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meneka K","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2021.05.014_bib0001","series-title":"Cannabidiol with Clobazam for treating seizures associated with Dravet syndrome. Technology appraisal guidance [TA614]","year":"2019"},{"key":"10.1016\/j.seizure.2021.05.014_bib0002","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2021.05.014_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2021.05.014_bib0004","unstructured":"Electronic medicines compendium. Summary of product characteristics: epidyolex 100mg \/ml oral solution. Updated 28 Aug 2020. Available at https:\/\/www.medicines.org.uk\/emc\/product\/10781#gref (accessed 18\/11\/2020)."},{"key":"10.1016\/j.seizure.2021.05.014_bib0005","series-title":"Vineland adaptive behaviour scales","author":"Sparrow","year":"2016"},{"key":"10.1016\/j.seizure.2021.05.014_bib0006","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2021.05.014_bib0007","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.05.014_bib0008","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:58:23Z","timestamp":1761011903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":8,"alternative-id":["S1059131121001655"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.05.014","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-center experience of cannabidiol use in adults with Dravet syndrome","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}